X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. It is being developed for the treatment of refractory chronic cough.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
The company intends to use the net proceeds of the offering primarily to fund BLU-5937 research and development activities, working capital needs and other general corporate purposes, as set out in the Supplement (as defined below).
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $153.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 18, 2022
Details:
The Company intends to use the net proceeds of the offering primarily to fund BLU-5937 research and development activities, working capital needs and other general corporate purposes, as set out in the supplement.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $153.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 14, 2022
Details:
BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics, for the treatment of refractory chronic cough.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Phase 2b SOOTHE trial which highlight BLU-5937 was well-tolerated with a low rate of taste-related adverse events (?6.5%) treatment emergent adverse event profile comparable to placebo used for the treatment of refractory chronic cough.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2021
Details:
BLU-5937, a highly selective P2X3 antagonist, is in development for RCC, chronic pruritus and other hypersensitization-related disorders.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2021
Details:
The SOOTHE Phase 2b trial is planned as a multicenter, randomized, double-blind, 4-week, parallel arm study evaluating three doses of BLU-5937 (12.5 mg, 50 mg and 200 mg BID) in 280 patients with refractory chronic cough versus placebo.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
Primary endpoint of placebo-adjusted reduction in awake cough frequency did not reach statistical significance. BLU-5937 was well tolerated with low impact on taste perception; safety profile comparable to placebo.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BLU-5937
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2020
Details:
BELLUS Health obtained clearance of U.S. IND for the Phase 2 clinical trial of BLU-5937 for the treatment of chronic pruritus associated with atopic dermatitis; trial expected to commence in second half of 2020.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
BELLUS Health to hold a KOL meeting featuring current therapies in development, including P2X3 antagonists, and provide an overview of Phase 2 RELIEF trial of BLU-5937 in refractory chronic cough.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
Details:
BELLUS completed patient dosing in its Phase 2 RELIEF clinical trial of BLU-5937 for the treatment of refractory chronic cough, with 52 patients completing treatment.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
Details:
The parties have terminated the 2017 license agreement pursuant to which the Company had exclusive rights to develop and commercialize the BLU-5937 Assets and henceforth.
Lead Product(s): BLU-5937
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BELLUS Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
